

## CURRICULUM VITAE

**ROGER BEHAR, M.D.**

**77 Veronica Avenue, Suite 102**

**Somerset, NJ 08873**

**(732) 246-1311**

### EDUCATION:

1970-1975 B.A. New York University, New York, New York  
1975-1978 University of Paris V. School of Medicine, Paris, France.  
1978-1980 M.D. New York Medical College, Valhalla, New York

### POST GRADUATE EDUCATION:

1980-1983 Straight Internal Medicine Residency,  
State University of New York at Stony Brook, Stony Brook, New York  
1985-1986 Neurology Residency, University of California at San Diego School of  
Medicine, San Diego, California

### ACADEMIC APPOINTMENTS:

1980-1983 Assistant Clinical Instructor, S.U.N.Y. at Stony Brook  
1985-1986 Chief Resident, Neurology, U.C.S.D. School of Medicine  
1986-2009 Clinical Instructor, Neurology, Robert Wood Johnson School of  
Medicine, U.M.D.N.J, New Brunswick, New Jersey  
2009-2012 Stroke Director, Saint Peters University Hospital, New Brunswick, New  
Jersey

### EMPLOYMENT:

1982-1983 Internist, Multiphasic, Inc. Hauppauge, New York  
1984-1985 Emergency Room, Walk-in Clinical Staff, Kaiser Permanente Zion  
Hospital, San Diego, California  
1986-1999 Private Practice, Matthew Menken, M.D., P.A. Princeton, New Jersey  
1999-Present Merged to form Princeton & Rutgers Neurology, P.A., Somerset, New  
Jersey

### BOARD CERTIFICATION:

National Board of Medical Examiners, 1981  
American Board of Internal Medicine, 1983  
Advanced Cardiac Life Support, A.H.A., 1983  
American Board of Psychiatry and Neurology, 1987  
American Board of Electrodiagnostic Medicine, 1988  
American Society of Neuroimaging, 1990

**LICENSURE:**

New York, 1981  
California, 1984  
New Jersey, 1986

**PROFESSIONAL AFFILIATIONS:**

American College of Physicians, 1980  
San Diego Neurologic Society, 1983  
American Academy of Neurology, 1984  
American Medical Association, 1985  
New Jersey Medical Society, 1986  
American Association of Electromyography and Electrodiagnostics, 1986  
American Society of Neuroimaging, 1987

**COMMITTEE:**

1989-1991 Institutional Review Panel, Princeton University

**PUBLICATIONS:**

1. Guillain-Barre syndrome associated with Hasimoto's disease, R. Behar, R. Perry, H. Powell, J. Neurology (1986) 233-233-36
2. Cytomegalovirus polyradiculopathy in AID's, R. Behar, C. Wiley, A. McCutchan, Neurology (1987) 37:557-61
3. Neurology Referral Patterns, M. Menken, R. Behar, Peter Lee, HMO Practice 1990, 4:57-60

**CLINICAL TRIALS:**

**List of Clinical Trials performed at Princeton and Rutgers Neurology, P.A.:**

1. **TEVA NEUROSCIENCE (PRINCIPAL INVESTIGATOR)**  
A double-blind, placebo controlled, randomized, multicenter study to assess the safety and clinical benefit of Rasagiline as an add on therapy to stable dose of dopamine agonists in the treatment of Early Parkinson's Disease.
2. **NOVARTIS (Sub I)**  
A 24-week, prospective, randomized, parallel-group, double-blind, multicenter study comparing the effects of Rivastgmine Patch 15 cm2 vs. Rivastigmine Patch 5 cm2 on activities of daily living and cognition in **patients with severe dementia of the Alzheimer's Type.**
3. **Upsher-Smith Laboratories, Inc. (Sub I)**

Protocol P09-004 and P09-005: A randomized, multicenter, double-blind, placebo-controlled, parallel-group, phase 3 study to evaluate the efficacy and safety of USL255 as adjunctive therapy in **patients with refractory partial onset seizures**.

4. **Upsher-Smith Laboratories, Inc. (Sub I)**

An open-label extension study to evaluate the safety of USL255 as adjunctive therapy in **Patients with refractory partial-onset seizures** who had participated in P09-004, a randomized, multicenter, double-blind, placebo controlled, parallel-group, phase 3 study

5. **Novartis (Sub I)**

A 48 week, multicenter, randomized, double-blind, parallel-group evaluation of the comparison efficacy, safety, and tolerability of Exelon 10 and 15 cm<sup>2</sup> patch in **Patients with Alzheimer's Disease** showing cognitive decline during an initial open-label treatment phase.